Vertex has secured a label expansion through the FDA's Commis | Vertex Pharmaceuticals has gained a label expansion from the ...
Vertex will acquire Crinetics Pharmaceuticals for $10 billion, its largest deal yet, adding an approved rare-disease drug to ...
The parent of bankESB and TruNorth Bank will end its 157-year history as a depositor-owned institution, in part to fund the ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S. Food and Drug Administration (FDA) has ...
VRTX gets FDA approval to expand Casgevy use in patients aged two and older with SCD or TDT, a first for genetic therapies in ...
Food and Drug Administration approved expanded use of Vertex Pharmaceuticals' gene therapy in ‌children as young as two with ...
Sionna Therapeutics targets cystic fibrosis with novel CFTR/NBD1 stabilization; key 2026 readouts and cash runway to 2028.
The Food and Drug Administration approved the use of Vertex Pharmaceuticals's sickle cell disease treatment, Casgevy, for patients as young as two years old. The agency said Wednesday that it issued a ...
Casgevy sickle cell gene therapy is now FDA-approved for children as young as two, opening access for 5,500 more U.S. kids.
The vertex at left represents the present day, while the opposite edge reaches back to when the universe was less than 1 ...
The FDA has approved a label expansion for Casgevy to include patients aged 2 years and older with sickle cell disease and ...
These companies don't typically compete directly with one another, but that might change soon.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results